top of page
News, Events and Updates
Search
Phase1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX2-73
Dec 11, 2014
Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for Treatment of Alzheimer's
Nov 17, 2014
Anavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference
Nov 10, 2014
Anavex to Present at SeeThruEquity Investor Conference in New York City
Nov 6, 2014
Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 & ANAVEX PLUS
Nov 3, 2014
Institutional Investor Lincoln Park Capital Increases Ownership in Anavex, Pays Over 25% Premium
Oct 26, 2014
Anavex Supports Alzheimer's Founding of America's 3rd Annual Concepts in Care Educational Conference
Sep 7, 2014
Anavex to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Sep 2, 2014
Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Clinical Trial
Aug 25, 2014
38
39
40
41
42
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
